tiprankstipranks
Advertisement
Advertisement

ATOS Stock Latest News

Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
The FlyAtossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
17d ago
ATOS
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
PremiumThe Fly
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
17d ago
ATOS
Atossa Therapeutics announces addition of two biopharma executives to team
PremiumThe Fly
Atossa Therapeutics announces addition of two biopharma executives to team
24d ago
ATOS
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
PremiumMarket News
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
2M ago
L
CLB
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
PremiumMarket News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
2M ago
CLB
IMA
Atossa Therapeutics Launches New $50 Million ATM Program
PremiumCompany AnnouncementsAtossa Therapeutics Launches New $50 Million ATM Program
2M ago
8K
ATOS
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
2M ago
L
CLB
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
2M ago
L
CLB
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
PremiumCompany Announcements
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
2M ago
8K
ATOS
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
PremiumThe Fly
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
2M ago
ATOS
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
PremiumCompany Announcements
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
2M ago
8K
ATOS
Atossa Therapeutics: Strategic Endoxifen Opportunity in DMD and PRV Creates Buy-Rated Upside at Disconnected Valuation
PremiumRatings
Atossa Therapeutics: Strategic Endoxifen Opportunity in DMD and PRV Creates Buy-Rated Upside at Disconnected Valuation
2M ago
ATOS
Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested
PremiumMarket NewsUpcoming Stock Splits This Week (February 2 to February 6) – Stay Invested
2M ago
PBM
AREB
Atossa Genetics trading halted, news pending
Premium
The Fly
Atossa Genetics trading halted, news pending
2M ago
ATOS
Atossa Therapeutics Sets 15-for-1 Reverse Stock Split
Premium
Company Announcements
Atossa Therapeutics Sets 15-for-1 Reverse Stock Split
3M ago
8K
ATOS
Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen
PremiumThe Fly
Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen
3M ago
ATOS
FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen
PremiumThe Fly
FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen
3M ago
ATOS
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
PremiumCompany Announcements
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
3M ago
8K
ATOS
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial
PremiumCompany Announcements
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial
3M ago
8K
ATOS
Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study
PremiumThe FlyAtossa Therapeutics receives “Study May Proceed” letter for breast cancer study
3M ago
ATOS
Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential
Premium
Ratings
Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential
4M ago
ATOS
Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics
Premium
Ratings
Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics
4M ago
ATOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >